To NASDAQ OMX Copenhagen A/S

Announcement no. 18-13 / Copenhagen, June 17, 2013

Topotarget announces that positive subtype data on angioimmunoblastic T-cell lymphoma (AITL) from the BELIEF trial with belinostat in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL) will be presented at the 12th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland, on June 19-22, 2013.

The belinostat abstract, which will be presented orally at the ICML conference, puts special emphasis to the BELIEF trial's subtype AITL, which has shown an objective response rate (ORR) of 45.5%.The abstract further concludes that the favorable safety profileobserved warrants further investigation of belinostat-based regimens to optimize outcomes for AITL.

"The PTCL subtype, AITL, represents 15-20% of all PTCL cases and we are hence very thrilled that belinostat shows a response rate of an astounding 45.5%, which places our compound at the top of available treatments in the indication", says Anders Vadsholt, CEO of Topotarget A/S.

Below is the full-length abstract, which will be presented on June 22, 2013.

Belinostat in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL) subtype angioimmunoblastic T-cell lymphoma (AITL): Results from the pivotal BELIEF trial.

S. Horwitz; O. O'Connor, W. Jurczak; A.Van Hoof; G. Hess; Z. Gasztonyl; J.K. Doorduijn; J. Walewski; P. Brown; A.Vranovsky; Sissolak; I. Auer; A. Duletic-Nacinovic; A. Shustov; S. Chawla; P. Knoblauch; G. Wulf; O. Visser; P. L. Zinzani;  T. Masszi.

Introduction:PTCL is a heterogeneous, aggressive disease with poor prognosis. AITL is a subtype representing 15-20% of PTCL. AITL treatment is similar to other forms of PTCL with 5-year OS rates of 10-32%.

Methods:BELIEF was a single-arm study of belinostat in patients with R/R PTCL after failure of